---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-25-000021"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:35:12.329016+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience Q3 net sales up 33% to $34M, net income $4.6M, raises FY sales growth outlook to 25-30%

## Summary
- Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).
- Net income $4.6M ($0.06 EPS) vs $1.9M ($0.02 EPS) prior year; adjusted EBITDA $6.4M (+120%).
- Gross margin 64.5% (+100 bps); sales & marketing expense as % of sales improved 170 bps to 25.8%.
- New FY 2025 outlook: net sales growth 25-30% (from 22-27%); reaffirms momentum in Tru Niagen and Niagen ingredients.
- Operational: launched AboutNAD platform, won NAD+ advertising challenge, expanded clinic network to 1,000+ sites.

## SEC filing metadata
- accession: 0001386570-25-000021
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000021/0001386570-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000021/cdxc-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-25-000021
- JSON: https://secwatch.observer/filing/0001386570-25-000021.json
- Plain text: https://secwatch.observer/filing/0001386570-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.